CCCC — C4 Therapeutics, Inc.

—
Nasdaq · Health Care · Biotechnology · CIK 1662579 ·
Last close
$2.53
Market Cap
$332.23M
52W High
$5.17
52W Low
$1.69
ADV30
2,960,042
Next earnings
2026-11-05

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 8,468,000 — -24,596,000 -21,843,000 331,800,000 32,425,000 103,632,000
Jun 2026 6,641,000 — -26,423,000 -23,635,000 359,404,000 78,610,000 112,139,000
Mar 2026 6,152,000 — -27,785,000 -25,129,000 328,861,000 61,274,000 94,614,000
Dec 2025 11,016,000 — -23,145,000 -20,486,000 359,075,000 74,603,000 102,488,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-79,629,000
Investing CF
$-99,973,000
Financing CF
$153,218,000
CapEx
$-523,000
Dividends Paid
—
Buybacks
$-253,000
EPS Diluted TTM
$-0.72
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-809,300,000
Inventory
—
Receivables
$1,405,000
ST Investments
$172,973,000
EBIT TTM
$-101,949,000
Pretax Income TTM
$-90,972,000
Interest Exp TTM
—
Analysts
8

Yahoo Snapshot (yfinance, live)

Total Revenue
$35,039,000
EBITDA
$-99,448,000
Free Cash Flow
$-43,664,000
Enterprise Value
$187,033,424
Total Cash
$253,663,008
Total Debt
$56,858,000
Shares Out
131,317,488
Trailing EPS
$-0.63
Book Value
$2.65
ROE
-48.1%
ROA
-19.3%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 35,947,000 -104,489,000 -104,994,000 359,075,000 102,488,000 256,587,000 -98,694,000
Dec 2024 35,584,000 -117,177,000 -105,316,000 349,602,000 133,616,000 215,986,000 -65,157,000
Dec 2023 20,756,000 -139,031,000 -132,493,000 376,451,000 130,337,000 246,114,000 -106,838,000
Dec 2022 31,096,000 -129,534,000 -128,175,000 430,840,000 141,606,000 289,234,000 -105,939,000

TTM Snapshot

Revenues TTM
$35,039,000
NetIncome TTM
$-101,416,000
OpCashFlow TTM
—
Assets (Latest)
$359,404,000
Forward EPS
$-0.92

Max Pain — expiry 2027-04-16

max pain strike: $4.00 · spot: $2.47 · call oi: 5,010 · put oi: 382
Expected Move to 2027-04-16: ±$1.25 (50.51%) — implied range $1.22 – $3.72 · ATM straddle on $2.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
JSPR Jasper Therapeutics, Inc. $344.06M $10.34 —
XFOR X4 Pharmaceuticals, Inc $315.53M $3.09 —
SLBT SL Science Holding Ltd $356.14M $0.64 —
SCTX Scribe Therapeutics, Inc. $298.64M $15.77 —
KYTX Kyverna Therapeutics, Inc. $297.14M $4.70 —

News headlines (Yahoo Finance, 1h cache)

Is C4 Therapeutics (CCCC) Outperforming Other Medical Stocks This Year?
2026-11-18 13:40 · Yahoo
C4 Therapeutics, Inc. (CCCC) Reports Q3 Loss, Lags Revenue Estimates
2026-11-05 13:35 · Yahoo
C4 Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights
2026-11-05 12:00 · Yahoo
C4 Therapeutics to Participate in Upcoming November Investor Conferences
2026-11-03 12:00 · Yahoo
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-11-02 21:01 · Yahoo
C4 Therapeutics, Inc. (CCCC) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
2026-10-29 13:00 · Yahoo
C4 Therapeutics Unveils Expansion of Discovery Platform Capabilities Utilizing Target-Centric Approach to Accelerate the Identification of Novel Molecular Glue Degraders
2026-10-29 11:00 · Yahoo
Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year?
2026-09-23 13:40 · Yahoo
C4 Therapeutics to Present New Biomarker Data on the Immunomodulatory Effects of Cemsidomide in Combination with Dexamethasone from its Phase 1 Relapsed/Refractory Multiple Myeloma Trial at the 23rd I
2026-09-03 11:00 · Yahoo
C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Tops Revenue Estimates
2026-08-11 12:15 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.